A unique new flexible and stretchable device, worn against the skin and capable of producing electrical energy by transforming the compounds present in sweat, was recently developed and patented by CNRS researchers from l’Université Grenoble Alpes and UC San Diego (USA). This cell is already capable of continuously lighting an LED, opening new avenues for the development of wearable electronics powered by autonomous and environmentally friendly biodevices.
This research was published in Advanced Functional Materials on September 25, 2019.
The potential uses for wearable electronic devices continue to increase, especially for medical and athletic monitoring. Such devices require the development of a reliable and efficient energy source that can easily be integrated into the human body. Using “biofuels” present in human organic liquids has long been a promising avenue.
Scientists from the Département de chimie moléculaire (CNRS/Université Grenoble Alpes), who specialize in bioelectrochemistry, decided to collaborate with an American team from UC San Diego, who are experts in nanomachines, biosensors, and nanobioelectronics. Together they developed a flexible conductive material consisting of carbon nanotubes, crosslinked polymers, and enzymes joined by stretchable connectors that are directly printed onto the material through screen-printing1.
The biofuel cell, which follows deformations in the skin, produces electrical energy through the reduction of oxygen and the oxidation of the lactate present in perspiration.
Once applied to the arm, it uses a voltage booster to continuously power an LED. It is relatively simple and inexpensive to produce, with the primary cost being the production of the enzymes that transform the compounds found in sweat. The researchers are now seeking to amplify the voltage provided by the biofuel cell in order to power larger portable devices.
The Latest on: Biofuel cell
via Google News
The Latest on: Biofuel cell
- CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapyon January 19, 2020 at 2:46 pm
A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped ...
- Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & Moreon January 17, 2020 at 8:23 am
Generation Bio closed a $110 million Series C round as it prepares to test its gene therapies ... Drug discovery software firm Schrödinger unveiled plans for an IPO as it continues to advance its own ...
- Novel protein positioning technique improves functionality of yeast cellson January 17, 2020 at 6:40 am
It is expected that these results will contribute to improved yeast functionality in cell surface engineering, which is utilized in a variety of fields such as bio-production and medicine. The journal ...
- Chemosensitization of prostate cancer stem cells in mice by angiogenin and plexin-B2 inhibitorson January 15, 2020 at 3:29 pm
were from Cell Signaling Technology and were used at 1:400 dilution. The polyclonal antibody against Ki-67 (EMD Millipore, Cat # AB9260) was used at 1:300 dilution, anti-PLXNB2 mAb17 (mad-in-house) ...
- bluebird bio Announces Launch in Germany of Zynteglo™ (autologous CD34+ cells encoding βA-T87Q-globin gene)on January 15, 2020 at 12:44 pm
4 Due to the highly technical and specialised nature of administering gene therapy in rare diseases, bluebird bio is working with institutions that have expertise in stem cell transplant as well as in ...
- Enhancement of FAK alleviates ventilator-induced alveolar epithelial cell injuryon January 15, 2020 at 10:08 am
Then, the fluid was centrifuged at 1500 × g for 10 min at 4 °C to collect cells, and the supernatant was centrifuged again at 12000 × g for 10 min at 4 °C to collect protein. In addition, the protein ...
- Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Productson January 15, 2020 at 3:00 am
/PRNewswire/ -- Artisan Bio, Inc., a stealth cell therapy engineering company, today announced it has entered into a global research and ...
- Cell Isolation/Cell Separation Market Progress and Manufacturer Contribution Highlighted Until 2029on January 15, 2020 at 12:45 am
Global News for Cell Isolation/Cell Separation Market Study 2020-2029, by Segment (Reagent, Instrument), Playing a Pivotal Role in Expanding by (Bio-Research Center, Hospital), Investment Analysis by ...
- Culture Media Market -Qualitative Opportunities 2025 |Bio-Rad Laboratories Inc, Caisson Laboratories, Inc, Cell Culture Technologies LLCon January 14, 2020 at 9:30 pm
Culture Media Market Analysis and Precise Outlook 2020-2025 ,This report presents an in-depth assessment of the ...
- IVERIC bio Announces Design for Second Pivotal Clinical Trial of Zimura® in Geographic Atrophy Secondary to Dry Age-Related Macular Degenerationon January 13, 2020 at 4:00 am
This mechanism of action could potentially prevent or slow down the degeneration of retinal pigment epithelial (RPE) cells providing the potential therapeutic rationale in GA secondary to dry AMD.
via Bing News